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Introduction
Endothelial cells are contact inhibited in their growth and lose 
the capacity to respond to growth factors when they reach 
 confl  uence. This phenomenon is mediated by different concurrent 
mechanisms. Molecules at cell to cell junctions, such as cad-
herins, may transfer signals that reduce the capacity of the cells to 
respond to proliferative stimuli (Dejana, 2004; Gumbiner, 2005). 
Cadherins are located at intercellular adherens junctions and are 
linked to different intracellular partners that include β-catenin, 
plakoglobin, p120, Src (Gumbiner, 2005), csk (Baumeister et al., 
2005), and density-enhanced phosphatase-1 (DEP-1)/CD148. 
β-catenin, plakoglobin, and p120 can also translocate to the 
nucleus and modulate cell transcription. In tumor cells, the neg-
ative effect of epithelial cadherin (E-cadherin) on cell growth is 
a result of its capacity to bind β-catenin and inhibit its translo-
ca  tion to the nucleus. This effect is detected in tumor cell lines 
in which cytosolic β-catenin ubiquitination and destruction is 
impaired (St Croix et al., 1998; Mueller et al., 2000; Gottardi 
et al., 2001; Stockinger et al., 2001; Bryant and Stow, 2005).
Endothelial cells express a cell-specifi  c cadherin called 
vascular endothelial cadherin (VEC). This protein exerts a neg-
ative effect on cell growth by binding VEGF receptor (VEGFR) 
type 2 and inhibiting its signaling activity (Carmeliet et al., 
1999; Shay-Salit et al., 2002; Lampugnani et al., 2003; 
Dejana, 2004). VEGF is a major growth factor for endothelial 
cells and plays an important role in the formation of new ves-
sels during embryogenesis and in proliferative diseases (Alitalo 
et al., 2005; Carmeliet, 2005; Ferrara and Kerbel, 2005). In 
blood   endothelium, the activities of VEGF are mediated by its 
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eceptor endocytosis is a fundamental step in con-
trolling the magnitude, duration, and nature of cell 
signaling events. Conﬂ  uent endothelial cells are con-
tact inhibited in their growth and respond poorly to the 
proliferative signals of vascular endothelial growth factor 
(VEGF). In a previous study, we found that the association 
of vascular endothelial cadherin (VEC) with VEGF receptor 
(VEGFR) type 2 contributes to   density-  dependent growth 
inhibition (Lampugnani, G.M., A. Zanetti, M.   Corada, 
T. Takahashi, G. Balconi, F.   Breviario, F.   Orsenigo, 
A.   Cattelino, R. Kemler, T.O. Daniel, and E. Dejana. 
2003. J. Cell Biol. 161:793–804). In the present study, 
we describe the mechanism through which VEC reduces 
VEGFR-2   signaling. We found that VEGF induces the 
clathrin-  dependent internalization of VEGFR-2. When 
VEC is absent or not engaged at junctions, VEGFR-2 is 
internalized more rapidly and remains in endosomal 
  compartments for a longer time. Internalization does not 
terminate its signaling; instead, the internalized receptor 
is phosphorylated, codistributes with active phospholipase 
C–γ, and activates p44/42 mitogen-  activated protein 
  kinase phosphorylation and cell proliferation. Inhibition of 
VEGFR-2 internalization reestablishes the contact inhibition 
of cell growth, whereas silencing the junction-associated 
density-enhanced   phosphatase-1/CD148 phosphatase 
restores VEGFR-2 internalization and signaling. Thus, 
VEC limits cell proliferation by retaining VEGFR-2 at 
the membrane and preventing its internalization into 
  signaling compartments.
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  interaction with two tyrosine kinase receptors, VEGFR-1 (fl  t-1) 
and -2 (fl  k/KDR), as well as neuropilins. The growth signals are 
transferred, to a large extent, through the activation of PLC-γ, 
PKC, and subsequently p44/42 MAPK (Takahashi et al., 1999, 
2001; Matsumoto et al., 2005; Singh et al., 2005).
We found that in contact-inhibited endothelial cells, 
VEGFR-2 forms a complex with VEC that results in the inhi-
bition of its tyrosine phosphorylation and, consequently, in the 
attenuation of MAPK activation. This effect was attributed to the 
phosphatase DEP-1/CD148 that, by binding β-catenin and p120, 
may associate with the cadherin–receptor complex and dephos-
phorylate the receptor (Lampugnani et al., 2003). In this study, 
we go further by describing another aspect of this phenomenon.
Upon activation with specifi  c ligands, growth factor recep-
tors are internalized via clathrin-dependent and - independent path-
ways. In many cases, this process leads to signaling termination via 
degradation of the activated receptor complex. Therefore, internal-
ization is considered an important mechanism through which cells 
may control the intensity and duration of signal transduction.
However, more recent fi  ndings indicate that internaliza-
tion is not just a sink through which receptors are degraded 
(Di Fiore and De Camilli, 2001; Miaczynska et al., 2004). On the 
contrary, some receptors, such as TGF-β, EGF, or NGF recep-
tors, can maintain their signaling activity from within intra-
cellular compartments (Suyama et al., 2002; Di Guglielmo 
et al., 2003; Bryant et al., 2005; Sigismund et al., 2005).
Little is known about the internalization pathways fol-
lowed by VEGFR-2 or their functional signifi  cance (Labrecque 
et al., 2003; Bhattacharya et al., 2005; Mitola et al., 2006). It has 
been reported that cadherins may infl  uence growth factor re-
ceptor internalization, but the extent to which they do depends 
on the cadherin or growth factor receptor. In tumor cell lines, 
N-cadherin forms a complex with FGF receptor 1 that inhibits 
its internalization and degradation. This causes a sustained FGF 
signaling and abnormal cell growth (Suyama et al., 2002). In 
contrast, E-cadherin cointernalizes with FGF receptor 1, which 
facilitates its nuclear translocation and signaling activity (Bryant 
and Stow, 2005; Bryant et al., 2005).
In this study, we analyzed the role of VEC on VEGFR-2 
internalization and signaling in endothelial cells. We found 
that the receptor is internalized more rapidly and effi  ciently 
when VEC is absent or not clustered at intercellular contacts. 
  Strikingly, internalization does not terminate receptor   signaling, 
which instead continues in endosomes. This may explain why 
VEC-null cells present increased and uncontrolled growth.
Results
VEC expression inhibits VEGFR-2 
internalization
We fi  rst investigated whether the establishment of cell to 
cell contact modulates VEGFR-2 internalization. Using freshly 
Figure 1.  VEC clustering at cell–cell con-
tacts inhibits VEGFR-2 endocytosis. (A) The 
internalization of VEGFR-2 from the plasma 
membrane was analyzed in sparse and con-
ﬂ  uent HUVECs treated with VEGF for 5 min. 
To detect the internalized receptor, cells were 
treated with a recombinant single chain anti-
body to human VEGFR-2, scFvA7, and acid 
washed before ﬁ   xation and processing for 
immunoﬂ   uorescence microscopy. Internalized 
VEGFR-2 appears in a vesicular pattern that 
is more abundant in sparse than in conﬂ  uent 
cultures. (bottom) The granular staining after 
different incubation lengths with VEGF was 
quantiﬁ   ed using the ImageJ program (see 
Materials and methods). The results (referred 
to as events per cell) reported in the graph are 
means ± SD (  error bars) of three independent 
experiments. At least seven random ﬁ  elds 
were analyzed for each time point in each 
experiment. (B) VEC-null and -positive conﬂ  u-
ent cultures were treated as described in A, 
but the anti–mouse VEGFR-2 clone Avas12α1 
was used. The micrographs show a typical 
vesicular labeling pattern after a 10-min treat-
ment with VEGF. The staining appears more 
abundant in VEC-null than in VEC-positive 
cells. (bottom) The time course of vesicular 
  labeling in response to VEGF was analyzed 
as described in A. The binding of the antibody 
does not activate VEGFR-2 nor does it induce 
its internalization (for details see Fig. S5, avail-
able at http://www.jcb.org/cgi/  content/full/
jcb.200602080/DC1). In A and B, nuclei 
stained with DAPI appear blue. *, P ≤ 0.05; 
**, P ≤ 0.01 by comparing sparse versus con-
ﬂ  uent (A, bottom) and VEC-null versus -positive 
(B, bottom) cells by analysis of variance and 
the Duncan test. Bars (A), 15 μm; (B) 20 μm.VE-CADHERIN AND VEGFR-2 INTERNALIZATION • LAMPUGNANI ET AL. 595
isolated human umbilical vein endothelial cells (HUVECs) 
stimu  lated with VEGF, we observed that VEGFR-2 endo-
cytosis, which was evaluated by immunofl  uorescence labeling 
of intracellular vesicular compartments, was signifi  cantly re-
duced by cell density (Fig. 1 A). Time course analysis revealed 
that in sparse cells, the number of receptor-positive vesicles in-
creased more rapidly and to a larger extent than in confl  uent 
cells (Fig. 1 A, bottom).
This fi  rst observation suggested that the establishment of 
cell to cell contact reduced VEGFR-2 internalization.   Because 
VEC plays a role in VEGFR-2 signaling, we investigated 
whether VEC could be involved inVEGFR-2 internalization. 
We compared syngenic endothelial cell lines differing for the ex-
pression of VEC. These cells had been characterized previously 
in detail and presented superimposable levels of VEGFR-2 (see 
Fig. 8; Lampugnani et al., 2002, 2003). As shown in Fig. 1 B, 
after the addition of VEGF, the number of VEGFR-2– containing 
vesicular compartments is markedly higher in the absence of 
VEC. Quantifi   cation of the amount of biotinylated receptor 
that was internalized, degraded, or recycled back to the plasma 
membrane is reported in Fig. 2. In VEC-null endothelium, the 
receptor is internalized more quickly and to a higher extent than 
in VEC-positive cells (Fig. 2, A and B).
In VEC-null cells, receptor internalization kinetics appear 
faster in biotinylation than in immunofl  uorescence experiments. 
This apparent discrepancy may be caused by internalization 
compartments, which can be measured in biotinylation experi-
ments because they are protected from glutathione (GSH) re-
duction but are not yet clustered in structures resolvable in 
immunofl  uorescence microscopy.
The overall amount of internalized receptor for the dura-
tion of the experiment is about fourfold more in VEC-null 
than -positive cells. Receptor degradation exceeds recycling by 
about fi  vefold in both cell types, but both parameters are signifi  -
cantly increased in the absence of VEC (Fig. 2, C and D). These 
data indicate that a higher amount of VEGFR-2 is internalized, 
degraded, and recycled in the absence of VEC.
Internalization of growth factor receptors may follow 
clathrin-dependent or -independent pathways. Among the lat-
ter, caveolae have been shown to regulate receptor internali-
zation directed toward degradation (Di Guglielmo et al., 
2003;   Sigismund et al., 2005). Our codistribution experi-
ments of VEGFR-2 with early endosomal antigen-1 (EEA-1) 
and   caveolin-1 show that VEGFR-2 internalizes mostly in 
EEA-1–positive early endosomes (Fig. 3) and to a very low 
  extent in caveolae.   Colocalization of VEGFR-2 and the caveolar 
component PV-1 (Stan et al., 2004; Stan, 2005) was also neg-
ligible (unpublished data). To control whether caveolae were 
ex  pressed correctly and to a comparable extent in both VEC-
null and -positive cells, we costained these structures with 
PV-1 and caveolin antibodies. As shown in Fig. S1 (available 
at http://www.jcb.org/cgi/  content/full/jcb.200602080/DC1), 
the extensive and comparable colocalization of caveolin and 
PV-1 could be observed in both cell types, suggesting structural 
integrity of the caveolar compartment.
The preferential distribution of VEGFR-2 in EEA-1–
  positive endosomes was further confi  rmed using immuno-EM 
(Fig. 3 C). In addition, silencing clathrin heavy chain expres-
sion either by siRNA (see Fig. 8 and Fig. S3, available at 
http://www.jcb.org/cgi/content/full/jcb.200602080/DC1) or dis-
rupting clathrin-coated pits by hypertonic medium blocked 
receptor internalization both in VEC-positive and -null cells (Fig. 4). 
In contrast, after incubation with fi  lipin at a concentration able 
to fully disrupt lipid rafts and caveolae (Schnitzer et al., 1994; 
Figure 2.  Internalization, degradation, and 
recycling of biotinylated VEGFR-2 are inhibited 
in VEC-positive cells. (A) Internalization and re-
cycling of VEGFR-2 was measured after cell 
surface biotinylation with thiol-cleavable Sulfo-
NHS-SS-Biotin. At selected time points, biotin 
was cleaved by GSH followed by immuno-
precipitation of VEGFR-2 and probing with 
HRP-streptavidin as described in Materials 
and methods. Recycling was measured as the 
amount of biotinylated receptor reappearing 
on the cell surface (and therefore not protected 
by GSH cleavage) at the indicated time points 
after 10 min of internalization in the presence 
of VEGF (indicated as 0 min in recycling 
panel). Total, total amount of labeled receptor 
after Sulfo-NHS-SS-Biotin labeling at 4°C (with-
out GSH treatment). GSH, treatment with re-
ducing GSH to remove any labeling on the 
residual surface-exposed receptor. (B) Densito-
metric analysis of internalization expressed 
as a percentage of total labeling. (C and D) 
Quantitation of receptor degradation and re-
cycling as a percentage of the amount of 
  receptor internalized after 10 min with VEGF. 
Although A presents a representative experi-
ment, the values in B–D are the means of four 
independent experiments ± SD (error bars). 
**, P ≤ 0.01; *, P ≤ 0.05 comparing VEC-null 
with -positive cells, respectively, by analysis of 
variance and the Duncan test.JCB • VOLUME 174 • NUMBER 4 • 2006  596
Andriopoulou et al., 1999), receptor internalization did not sig-
nifi  cantly change (Fig. 4).
We also performed experiments at different time points 
(5, 7, 10, 20, and 30 min) after the addition of VEGF in VEC-
null and -positive cells using caveolin and PV-1 as markers of 
caveolae and EEA-1 and Rab-5 as markers of early endosomes. 
At all time points considered, we could not see internalized 
VEGFR-2 in vesicles positive to either caveolin or PV-1 but 
only in bona fi  de early endosomes (unpublished data). These 
data strongly suggest that, at least within the experimental con-
ditions used, VEGFR-2 endocytosis in endothelial cells is mostly 
clathrin dependent.
Internalized VEGFR-2 retains 
signaling activity
In the absence of VEC, endothelial cells respond more effec-
tively to growth signals transferred by VEGFR-2. From the 
aforementioned observations, we concluded that VEGFR-2 is 
internalized more quickly and to a larger extent in VEC-null 
cells than in VEC-positive cells. Therefore, we asked whether 
the receptor retains its signaling activity when sequestered in 
intracellular compartments.
We fi rst tested whether the internalized receptor retained tyro-
sine phosphorylation by cell fractionation on an iodixanol gradient 
(Yeaman et al., 2001). Antibodies recognizing phosphotyrosine 
(PY) 1214– and PY1054/59–VEGFR-2 were used. As shown in 
Fig. 5, in the absence of VEC, a higher amount of phosphorylated 
VEGFR-2 is detected in intracellular fractions, whereas in the 
presence of VEC, the phosphorylated receptor remains preferen-
tially in fractions corresponding to peripheral plasma membranes.
Phosphorylation of VEGFR-2 tyrosine 1175 is required 
for binding and activation of PLC-γ, which is the major effector 
of VEGF-mediated cell proliferation (Takahashi et al., 2001). By 
using antibodies specifi  c for PY1175–VEGFR-2, we observed 
that in the absence of VEC, a higher amount of internalized 
receptor was phosphorylated at this specifi  c tyrosine (Fig. 6, 
A and B). Consistently, more internalized PY1175–VEGFR-2 
was found in sparse than in confl  uent HUVECs (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200602080/DC1).
To further prove that PLC-γ could be activated by the inter-
nalized receptor, we stained the cells with antibodies directed 
to the active PY783–PLC-γ. As shown in Fig. 7,   active PLC-γ 
  codistributes with internalized VEGFR-2 more effectively in 
the absence than in the presence of VEC.
Figure 3.  Internalized VEGFR-2 colocalizes with EEA-1– 
positive compartments by immunoﬂ  uorescence  analysis. 
  HUVECs, VEC-null, and VEC-positive cells were double la-
beled for VEGFR-2 and either EEA-1 or caveolin-1. Cells were 
activated with VEGF for 10 min. (A) Representative exam-
ples of confocal images for each antigen and their respective 
merges (boxed areas; 3.5-fold magniﬁ  cation) are shown for 
conﬂ  uent HUVECs after treatment with VEGF. VEGFR-2 was 
revealed with an AlexaFluor488-conjugated secondary anti-
body and is shown in green. EEA-1 and caveolin revealed 
with AlexaFluor647-conjugated secondary antibodies are 
shown in red. Nuclei appear blue after DAPI staining. Bars, 
10 μm. (B) To quantify colocalization events, images were an-
alyzed using the ImageJ colocalization plugin (as described 
in Materials and methods). The graphs present the number of
colocalization events normalized for the number of VEGFR-2–
positive compartments. After VEGF treatment,  45–55% 
of VEGFR-2–positive compartments showed colocalization 
with EEA-1 in all of the situations examined. Colocalization of 
internalized VEGFR-2 with caveolin-1 was negligible. Values 
are the mean of at least three experiments ± SD (error bars). 
In each experiment, at least ﬁ  ve random ﬁ  elds were analyzed 
for each point. *, P ≤ 0.01 by t test. (C, a and b) Immuno-
gold labeling of EEA-1 (10 nm gold; arrows) and VEGFR-2 
(15 nm gold; arrowheads) on an ultrathin cryosection of 
VEC-null and -positive cells treated with VEGF for 10 min. 
The panels display VEGFR-2 labeling of EEA-1–positive endo-
somes in VEC-null rather than in VEC-positive cells. (c and d) 
Under the same conditions, morphologically identiﬁ  ed caveo-
lae are devoid of VEGFR-2. Bar (a), 227 nm; (b) 222 nm; 
(c) 350 nm; (d) 370 nm.VE-CADHERIN AND VEGFR-2 INTERNALIZATION • LAMPUGNANI ET AL. 597
Inhibition of VEGFR-2 internalization 
affects its proliferative signaling
Overall, the aforementioned data indicate that VEC limits receptor 
activation and internalization. In the absence of this   protein, the 
receptor is internalized more effi  ciently and retains its active state 
for a longer time, leading to continuous proliferative signaling.
To further test this hypothesis, we prevented receptor 
  internalization by silencing clathrin with two specifi  c siRNAs 
Figure 4.  VEGFR-2 is internalized through 
a clathrin-dependent pathway. (A) VEC-null 
and -positive cells were transfected with either 
Stealth siRNA targeting the mouse clathrin 
heavy chain or negative Stealth siRNA control 
duplex (and used 72 h later), or the cells were 
treated with hypertonic medium (0.45 M 
  sucrose for 30 min) or 1 μg/ml ﬁ  lipin for 1 h. 
The micrographs show VEGFR-2 immuno-
ﬂ  uorescence staining after VEGF treatment for 
10 min. Both clathrin heavy chain siRNA and 
hypertonic medium strongly reduced VEGFR-2 
vesicular patterning both in VEC-null and -positive 
cells. Using ﬁ  lipin to interfere with the caveolar 
compartment had no effect on either cell type. 
The negative Stealth siRNA control duplex 
  produced results that were indistinguishable 
from untreated cells (not depicted). Nuclei 
  appear blue after DAPI staining. Bar, 20 μm. 
(B) Column graphs represent VEGFR-2 vesicu-
lar labeling in VEGF-treated cells quantiﬁ  ed by 
ImageJ. Ctr, control; HM, hypertonic medium. 
Values normalized per cell are the mean of 
three independent experiments ± SD (error 
bars). In each experiment, at least ﬁ  ve inde-
pendent ﬁ  elds were analyzed for each point. 
*, P ≤ 0.01 versus control values by analysis 
of variance and the Dunnet test.
Figure 5.  VEC expression reduces the amount of PY–VEGFR-2 in internal compartments. Extracts of VEGF-treated VEC-null and -positive cells were fraction-
ated on an iodixanol gradient as described in Materials and methods. Samples representative of the total protein content of each fraction were analyzed 
by SDS-PAGE and Western blotting. As expected, VEC concentrates in lower density fractions corresponding to plasmatic membranes, whereas clathrin and 
EEA-1 are enriched in higher density fractions corresponding to internal membranes (Yeaman et al., 2001). Upon stimulation with VEGF, PY1214–VEGFR-2 
is enriched in fractions corresponding to the internal membranes in VEC-null cells. The graph shows the ratio between the phosphorylated receptor and the 
total receptor present in each fraction. For quantiﬁ  cation, in each fraction, we considered the band with the molecular mass of the mature form of the receptor 
at the plasma membrane ( 210 kD; see fraction 1 and arrowheads; Takahashi and Shibuya, 1997). We chose this band by making the assumption that 
full-length VEGFR-2 represents the signaling form of the receptor. At increasing density, a lighter band appears both in VEC-null and -positive cells (asterisks). 
It is likely that this band derives from VEGFR-2 processing in internal compartments (for instance, proteolytic or intermediate synthesis products) and is indeed 
not present in the peripheral membrane fractions. Comparable results were obtained using an antibody to PY1054/59–VEGFR-2 (not depicted).JCB • VOLUME 174 • NUMBER 4 • 2006  598
(Figs. 4, 8, and S3) that target independent sequences of clathrin 
heavy chain messenger. As expected, VEGF-induced phosphor-
ylation of VEGFR-2 and activation of p44/42 MAPK were 
higher in the absence than in the presence of VEC (Fig. 8). 
When siRNA clathrin was applied to VEC-null cells, both re-
ceptor and MAPK phosphorylation dropped to values compara-
ble with those of VEC-positive cells. In contrast, in the presence 
of VEC, the effect of siRNA clathrin was either weak or 
  undetectable. Consistently, the inhibition of MAPK activation 
was also observed by treating the cells with hypertonic medium, 
whereas treatment with fi  lipin did not modify MAPK activa-
tion in response to VEGF either in VEC-positive or -null cells 
(unpublished data). Overall, these results strongly suggest that 
internalization protects the receptor from dephosphorylation 
and, therefore, increases and prolongs its proliferative signaling.
VEC association with VEGFR-2 
is required for receptor retention 
at the plasma membrane
We then investigated the mechanism through which VEC in-
hibits VEGFR-2 internalization. In a previous study, we found 
that VEC forms a complex with VEGFR-2, and we analyzed the 
domains of VEC involved in this process (Lampugnani et al., 2003). 
VEC mutants lacking either the β-catenin– or p120-binding 
  domains were unable or less effi  cient, respectively, to coimmuno-
precipitate VEGFR-2. We found that these mutants were 
also unable to signifi  cantly prevent VEGFR-2 internalization 
(Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200602080/DC1), suggesting that receptor internalization is 
reduced as a consequence of binding to VEC.
Similar to E-cadherin (for review see Bryant and Stow, 
2004), VEC can be internalized through clathrin-coated pits 
(Xiao et al., 2005). We tested whether VEC codistributes with 
VEGFR-2 in intracellular compartments. As reported in Fig. 9 
upon VEGF activation, no signifi  cant codistribution of VEC 
with VEGFR-2–positive vesicles is detected in VEC-positive 
cells and HUVECs (Fig. S4). Only junctional colocalization 
can be observed (Fig. 9). The lack of codistribution in internal 
compartments was confi   rmed by immuno-EM (unpublished 
data). Collectively, these data suggest that the receptor internal-
izes upon dissociation from VEC.
VEGFR-2 phosphorylation is required 
for internalization and signaling
In previous studies, we showed that the phosphatase DEP-1/
CD148 can reduce VEGFR-2 signaling. DEP-1/CD148 can 
associate with β-catenin and p120 (Holsinger et al., 2002; 
Palka et al., 2003) and with the VEC–VEGFR-2 complex, re-
ducing VEGFR-2 phosphorylation (Lampugnani et al., 2003). 
  Therefore, we tested whether DEP-1/CD148 could also reduce 
receptor internalization.
As reported in Fig. 10 A, in endothelial cells transfected 
with DEP-1/CD148 siRNA, VEGFR-2 internalization is signi-
fi  cantly higher. This effect is accompanied by an increase in 
VEGFR-2 phosphorylation and MAPK activation (Lampugnani 
et al., 2003). These data suggest that retention of VEGFR-2 at 
the membrane by VEC allows its dephosphorylation by DEP-1/
CD148 and limits its internalization and signaling.
Discussion
In this study, we report a novel aspect of the mechanism through 
which VEC expression and clustering inhibits VEGFR-2 prolif-
erative signaling. We found that in the absence of VEC or in 
conditions in which VEC is not clustered at adherens junctions 
as in sparse cells, VEGFR-2 is endocytosed to a higher extent in 
intracellular compartments, from where it maintains its  signaling 
activity. VEC could therefore reduce receptor activity by in-
hibiting VEGFR-2 internalization and promoting its  inactivation 
at the cell surface.
In our experimental conditions, VEGFR-2 is internal-
ized in early endosomes mostly through a clathrin-dependent 
pathway. We were unable to detect caveolin-1–positive vesi-
cles containing VEGFR-2, and we could not inhibit receptor 
internalization using a caveolae-perturbing drug such as   fi  lipin 
(Schnitzer et al., 1994; Andriopoulou et al., 1999). Other 
  studies found the codistribution of VEGFR-2 with caveolin-1 
(Labrecque et al., 2003; Bhattacharya et al., 2005; Ikeda et al., 
2005), and we cannot exclude that under different experimental 
conditions, VEGFR-2 may be internalized through caveolae. 
Figure 6.  Internalized VEGFR-2 is phosphorylated at tyrosine 1175. 
(A) VEC-null and -positive cells were stimulated with VEGF as in Fig. 1, ﬁ  xed, 
and processed for immunoﬂ  uorescence microscopy. The vesicular labeling 
pattern observed with PY1175–VEGFR-2 antibody after stimulation with 
VEGF was signiﬁ  cantly more abundant in VEC-null than in VEC-positive 
cells. Nuclei appear blue after DAPI staining. Bar, 20 μm. (B) Images were 
analyzed by ImageJ to quantify PY115–VEGFR-2–positive compartments 
(see Materials and methods). The graph presents the mean ± SD (error 
bars) calculated from 18 random ﬁ  elds that were analyzed through ImageJ 
in ﬁ  ve independent experiments and is normalized to the number of cells 
per ﬁ  eld. In each experiment, at least three random ﬁ  elds were analyzed. 
*, P ≤ 0.01 comparing VEC-null with -positive cells after VEGF by analysis 
of variance and the Duncan test.VE-CADHERIN AND VEGFR-2 INTERNALIZATION • LAMPUGNANI ET AL. 599
However, the observed association with caveolin-1 may also 
represent a mechanism of receptor compartmentalization at the 
plasma membrane. It was found that caveolin-1 would form 
a molecular complex with VEGFR-2 that inhibits receptor acti-
vation in resting cells. Upon activation of the cells with VEGF, 
caveolin-1 is phosphorylated, and the complex rapidly disso-
ciates (Labrecque et al., 2003). Thus, it is tempting to specu-
late that similar to TGF-β receptor (Di Guglielmo et al., 2003), 
once VEGFR-2 is released from the caveolin-1 complex, it 
  becomes available for internalization in clathrin-coated pits. 
In agreement with this model, the overexpression of caveolin-1 
in transgenic mice reduces permeability and angiogenic response 
to VEGF (Bauer et al., 2005).
It has been reported that VEGFR-2 internalization and degra-
dation are regulated by ubiquitination through a Cbl-dependent 
mechanism (Duval et al., 2003) or C-tail serine phosphorylation 
by activated PKC (Singh et al., 2005). These mechanisms may 
coexist and may be responsible for the amount of receptor degra-
dation reported here.
Our observations support the hypothesis that internal-
ized VEGFR-2 maintains its activity. These data are in agree-
ment with recent publications indicating that signaling through 
Figure 7.  Colocalization of internalized VEGFR-2 and acti-
vated PLC-𝗄. (A) VEC-null and -positive cells were labeled 
in vivo with antibodies to VEGFR-2, stimulated with VEGF as 
in Fig. 6, acid washed, ﬁ  xed, and processed for immunoﬂ  uo-
rescence microscopy. Cells were double labeled with an anti-
body that recognizes PLC-γ only when phosphorylated at 
tyrosine 783. VEGFR-2 was revealed with an AlexaFluor488-
conjugated secondary antibody and is shown in green. 
PY783–PLC-γ, which was revealed with an AlexaFluor647-
conjugated secondary antibody, is shown in red. For each 
cell type, the bottom panel on the right (threefold magniﬁ  ca-
tion of the boxed areas) shows the colocalization of VEGFR-2 
and PY783–PLC-γ (pink) set upon the VEGFR-2 background 
(gray). This was obtained through the ImageJ colocalization 
plugin (see Materials and methods for details). Arrows point 
to the colocalization of PY783–PLC-γ and VEGFR-2. Bars, 
10 μm. (B) The confocal images were analyzed through 
  ImageJ to calculate the number of colocalization events. These 
values, which were normalized over the number of VEGFR-2–
positive compartments per cell, are presented in the graph. 
After VEGF treatment, colocalization was about ﬁ  vefold 
higher in VEC-null than in VEC-positive cells. Values in the 
graph are the mean from three independent experiments 
± SD (error bars). In each experiment, each point was calcu-
lated from at least ﬁ  ve random ﬁ  elds. *, P ≤ 0.01 comparing 
VEC-null with -positive cells after VEGF by analysis of vari-
ance and the Duncan test.
Figure 8.  Silencing clathrin expression in-
hibits VEGFR-2 phosphorylation and signaling 
in VEC-null cells. VEC-null and -positive cells 
were transfected with Stealth siRNA-targeting 
mouse clathrin heavy chain. Two oligonucleo-
tides (a and b; respective sequences are re-
ported in Materials and methods) were used 
that target two independent sequences of the 
clathrin heavy chain mRNA. Negative Stealth 
siRNA duplex was used as a control. After 72 h, 
cells were treated with VEGF or control me-
dium for 10 min. They were then extracted and 
processed for Western blotting. Clathrin siRNA 
reduced clathrin heavy chain levels by  75 
(oligonucleotide a) and 90% (oligonucleotide b) 
in both cell types. VEGFR-2 phosphorylation 
at tyrosine 1214 and p44/42 MAPK phos-
phorylation in response to VEGF were strongly 
inhibited in VEC-null cells, whereas these pa-
rameters were only barely affected in VEC-
positive cells. Comparable results were obtained 
for PY1054/59–VEGFR-2 (not depicted). The 
graphs show the quantiﬁ  cation of these effects 
as means ± SD (error bars) of ﬁ  ve independent experiments. Fold increase after VEGF is shown for PY1214–VEGFR-2 and phospho-p44/42 MAPK. 
*, P ≤ 0.01 versus negative siRNA by variant analysis and the Dunnet test.JCB • VOLUME 174 • NUMBER 4 • 2006  600
growth factor receptors does not occur only at the cell mem-
brane but may continue even more effectively from intracellular 
compartments (Di Fiore and De Camilli, 2001; Sorkin and Von 
Zastrow, 2002; Miaczynska et al., 2004; Le Roy and Wrana, 
2005). Clathrin-dependent internalization of TGF-β in early en-
dosomes, where the Smad2 anchor SARA is enriched, promotes 
TGF-β signaling (Di Guglielmo et al., 2003). EGF receptor is 
internalized shortly after ligand addition in intracellular com-
partments together with its downstream signaling factors shc, 
Grb2, and mSOS (Di Guglielmo et al., 1994) and maintains 
its signaling activity (Pennock and Wang, 2003). Similarly, 
the specifi  c activation of endosome-associated PDGF receptor 
leads to the activation of its major signaling pathways (Wang 
et al., 2004). Thus, as for VEGFR-2, endocytic transport is im-
portant not only for receptor turnover but also for regulating 
signal transduction and for mediating the formation of special-
ized signaling complexes.
A novel aspect of our work is that VEC inhibits VEGFR-2 
internalization, thereby reducing its cell growth signaling activity. 
How can VEC inhibit receptor endocytosis? A likely hypothesis 
is that VEC retains VEGFR-2 at the membrane by binding to it. 
In addition to our studies, others have reported (Shay-Salit et al., 
2002; Lampugnani et al., 2003; Weis et al., 2004; Lambeng 
et al., 2005) that VEGFR-2 couples with VEC. This process 
  requires the binding of VEC to β-catenin and, to a lesser extent, 
to p120. In the present study, we found that mutants of VEC 
lacking the cytoplasmic domain responsible for binding either 
β-catenin or p120 and unable to associate with VEGFR-2 
  (Lampugnani et al., 2003) do not prevent VEGFR-2 internaliza-
tion. This supports the idea that VEC–VEGFR-2 coupling is re-
quired to inhibit receptor endocytosis.
Cadherins themselves are endocytosed via several dif-
ferent routes, including clathrin-dependent (Le et al., 1999; 
  Palacios et al., 2002; Ivanov et al., 2004; Izumi et al., 2004) 
and -independent pathways (Akhtar and Hotchin, 2001; Paterson 
et al., 2003). Therefore, cotraffi  cking of receptor and cadherin 
complexes is possible (for reviews see Bryant and Stow, 2004, 
2005; Cavallaro and Christofori, 2004). However, under our 
  experimental conditions, we could detect VEC in intracellular 
compartments (Xiao et al., 2005), but we could not see codistri-
bution with the receptor. Thus, it is likely that the receptor dis-
sociates from VEC before internalization (Fig. 9).
In a previous study, the phosphatase DEP-1/CD148 was 
found to play a role in the inhibitory effect of VEC on VEGR-2 
signaling (Lampugnani et al., 2003). This phosphatase associ-
ates with VEC through its binding to β-catenin and p120 and, 
in this way, reduces VEGFR-2 phosphorylation (  Lampugnani 
et al., 2003). We report that DEP-1/CD148 could prevent 
VEGFR-2 internalization along with the reduction of recep-
tor phosphorylation and signaling. Therefore, it is possible that 
VEC, by retaining VEGFR-2 at the cell surface, allows its de-
phosphorylation by DEP-1/CD148, which, in turn, inhibits its 
internalization and signaling.
Besides VEC, VEGFR-2 was found to bind to integrins (Soldi 
et al., 1999). Another study reported that when cells are plated 
on collagen I, the phosphatase SHP2 can associate with VEGFR-2 
and stimulate its internalization. SHP2 activates Src, which in 
turn   activates dynamin II–dependent receptor internalization 
(Mitola et al., 2006). Interestingly, this phenomenon does not 
occur when cells are plated on vitronectin, and SHP2 does not 
Figure 9.  VEC does not codistribute with VEGFR-2 in internal  compartments. 
VEC-positive cells were treated with VEGF for 10 min, double stained for 
VEGFR-2 and VEC, and analyzed by confocal microscopy.   Besides junc-
tional staining, VEC did not show any obvious vesicular pattern. VEGFR-2 
and VEC appeared to codistribute only at cell–cell contacts and not in intra-
cellular compartments. The bottom panel on the right (2.6-fold magniﬁ  cation 
of the boxed areas) shows the colocalization of VEGFR-2 and VEC (yellow) 
set upon the VEC background (gray). This was obtained through the colo-
calization plugin of ImageJ (see Materials and methods for details). Arrows 
point to the junctional colocalization of VEGFR-2 and VEC. Bars, 10 μm.
Figure 10.  DEP-1/CD148 silencing in VEC-positive cells in-
creases internalization, tyrosine phosphorylation, and activity 
of VEGFR-2. VEC-positive cells were transfected with either 
Stealth siRNA-targeting mouse DEP-1/CD148 or a negative 
Stealth siRNA control duplex. After 72 h, cells were treated 
with VEGF for 10 min and either ﬁ  xed and processed for immuno-
ﬂ   uorescence microscopy or extracted and processed for 
Western blotting. DEP-1/CD148 siRNA reduced DEP-1/
CD148 protein by  45% (B). (A) VEGFR-2–positive vesicular 
compartments were found to be signiﬁ  cantly higher (>80%) 
in VEGF-treated cells after transfection with DEP-1/CD148 
siRNA. Means of three independent experiments ± SD (error 
bars) are shown. In each experiment, at least ﬁ  ve  random 
ﬁ  elds were analyzed. *, P ≤ 0.01 comparing negative with 
DEP-1 siRNA interference by analysis of variance and the Duncan test. (B) Phosphorylation of VEGFR-2 at tyrosine 1214 and of p44/42 MAPK was 
  increased by  80 and 60%, respectively, after DEP-1/CD148 siRNA transfection in VEGF-treated cells.VE-CADHERIN AND VEGFR-2 INTERNALIZATION • LAMPUGNANI ET AL. 601
bind to VEGFR-2 (Mitola et al., 2006). These observations sug-
gest that the capacity of different adhesive proteins to complex 
with growth factor receptors and modulate their internalization 
and signaling may be a general paradigm. In this way, cells may 
modulate their growth and survival as a function of density and 
interaction with specifi  c matrix proteins.
In conclusion, the results reported in this study are con-
sistent with the idea that VEGFR-2 proliferative signaling is in-
creased by endocytosis. The inhibitory role of VEC is likely that 
of binding and retaining the receptor at the cell surface, prevent-
ing its endocytosis, and favoring inactivation by DEP-1/CD148. 
This suggests that the modulation of VEC–VEGFR-2 complex 
formation may be a novel strategy to regulate VEGF proliferative 
signaling and, therefore, to inhibit or stimulate angiogenesis.
Materials and methods
Primary antibodies
For the detection of VEGFR-2, anti–human VEGFR-2 (single chain recom-
binant; clone scFvA7 with E tag; RDI and Fitzgerald) and anti–mouse 
VEGFR-2 (rat clone Avas12α1; RDI and Fitzgerald) were used for immuno-
ﬂ  uorescence; rabbit polyclonal C-1158 (sc504; Santa Cruz Biotechnology, 
Inc.) was used for Western blotting. Antibodies to tyrosine-phosphorylated 
VEGFR-2 were rabbit polyclonal PY1214 and PY1054/59 (Biosource 
  International) and rabbit polyclonal PY1175, which was provided by 
M. Shibuya (University of Tokyo, Tokyo, Japan). Antibodies to clathrin 
heavy chain were mouse monoclonal cloneX22 (Afﬁ  nity BioReagents, Inc.) 
for immunoﬂ  uorescence and mouse monoclonal clone 23 (R&D Systems) 
for Western blotting. Antibody to EEA-1 was goat polyclonal N-19 
(sc-6415; Santa Cruz Biotechnology, Inc.); antibody to caveolin-1 was rabbit 
polyclonal N-20 (sc-894; Santa Cruz Biotechnology, Inc.); and antibody 
to VEC was goat polyclonal C-19 (sc-6458; Santa Cruz Biotechnology, 
Inc.) and mouse monoclonal BV6 and BV9 (produced in our laboratory; 
  Corada et al., 2001). Antibody to PY783-PLCγ, total p42/44 MAPK, and 
phospho-p42/44 MAPK was rabbit polyclonal (Cell Signaling). Antibody 
to DEP-1/CD148/CD148 was goat polyclonal (R&D Systems), and anti-
body to PV-1 was rat monoclonal (provided by R. Stan, Dartmouth Medical 
School, Lebanon, NH).
Cell types and culture conditions
Endothelial cells with a homozygous null mutation of the VEC gene (VEC 
null) and the cell lines derived from them through retroviral gene transfer 
and expressing wild-type (VEC positive) or various VEC mutant constructs 
were generated and characterized as described previously in detail 
  (Lampugnani et al., 2003). For all of the experiments, 50,000 cells/cm
2 
(to reach conﬂ  uence within 24 h) were seeded in complete culture medium 
and cultured without medium change for 72 h. Cells were then washed 
once with MCDB 131 (Life Technologies) and starved in 1% BSA in MCDB 
131 (starving medium) for 18–20 h. 2 h before activation, cells were 
washed once with MCDB 131 and further incubated in fresh starving 
  medium. Cells were treated with 80 ng/ml VEGF (human recombinant 
VEGF 165; PeproTech) in fresh starving medium (fresh starving medium 
alone was used for controls) for the indicated intervals at 37°C. If not 
  otherwise indicated, VEGF treatment was for 10 min.
HUVECs were cultured in MCDB 131 with endothelial cell supple-
ments as described previously (Lampugnani et al., 2003). For the experi-
ments 1,800 and 42,000 cells/cm
2 were seeded to obtain sparse and 
conﬂ  uent cultures, respectively. HUVECs were then treated as described in 
this section for mouse endothelial cells except that starving was reduced to 
6 h before stimulation with VEGF.
Filipin and hypertonic treatments
Caveolae organization was altered by treatment with 1 μg/ml ﬁ  lipin 
  (ﬁ  lipin III from Streptomyces ﬁ  lipinensis; Sigma-Aldrich) for 1 h (Schnitzer 
et al., 1994; Andriopoulou et al., 1999). Clathrin pit–mediated endocyto-
sis was inhibited using hypertonic medium (0.45 M sucrose in MCDB 131 
with 1% BSA) for 30 min to affect as described previously (Heuser and 
  Anderson, 1989; Ehrlich et al., 2001). Cells were then stimulated and 
assayed as indicated in the speciﬁ  c sections.
RNA interference
Cells were seeded as described in Cell types and culture conditions. 20 h 
later, cells were washed once with OptiMEM (Life Technologies) and trans-
fected with 40 nM of Stealth oligonucleotides (Invitrogen) using 2 μl/ml 
LipofectAMINE 2000 (Invitrogen) in OptiMEM according to the manufac-
turer’s instructions. After 5 h, the transfection medium was removed, and 
complete culture medium was added. Cells were cultured for a further 72 h 
before stimulation and processing for immunoﬂ  uorescence and extraction.
Stealth oligonucleotides were used as follows: a, 5′-G  C  A  G  U  U  G  U  U-
C  A  U  A  C  C  C  A  U  C  U  U  C  U  U  A  -3′ (start nucleotide was 2,118 bases down-
stream of the start codon); b, 5′-G  A  A  G  A  A  C  U  C  U  U  U  G  C  C  C  G  G  A  A  A  U  U  U  A  -3′ 
(start nucleotide was 1,284 bases downstream of the start codon) to target 
mouse clathrin heavy chain; and 5′-U  C  G  A  G  C  C  A  G  U  G  A  G  C  A  U  G  U  U  U  G  G-
A  A  A  -3′ (start nucleotide was 4,023 bases downstream of the start codon) 
to target mouse DEP-1/CD148. As a control, a Stealth siRNA-negative 
control duplex oligonucleotide (Invitrogen) with a C/G content equivalent 
to the positive oligonucleotide was used.
Internalization assays
Microscopy. Cells were treated in vivo with anti–VEGFR-2 antibody and 
acid washed before ﬁ  xation (Ehrlich et al., 2001; Di Guglielmo et al., 
2003) as follows. We used monoclonal antibodies to the extracellular 
domain of human and mouse VEGFR-2 (see Primary antibodies) that are 
described by the manufacturers to be devoid of biological activity. As this 
aspect was crucial to the assay, we tested the effect of these antibodies on 
basal and VEGF-stimulated phosphorylation and internalization of VEGFR-2.
We found that these antibodies do not stimulate the phosphorylation 
of VEGFR-2 in either condition. These results are reported in Fig. S5 
  (available at http://www.jcb.org/cgi/content/full/jcb.200602080/DC1). 
Anti–mouse VEGFR-2 was dialyzed for 3 h against PBS (with one change) 
to remove azide. Cells were precooled for 30 min on ice and treated with 
10 μg/ml of antibody for 1 h on ice with gentle agitation. Before stimula-
tion, cells were washed with ice-cold 1% BSA in MCDB 131 to remove 
unbound antibody, and fresh medium was added. Cells were stimulated 
with 80 ng/ml VEGF and transferred to 37°C. After the indicated time 
intervals, cells were placed on ice and acid washed (three washes with 
ice-cold 50 mM glycine in Ca
2+/Mg
2+ HBSS, pH 2.5, and two washes with 
Ca
2+/Mg
2+ HBSS, pH 7.5) to remove the antibody from the cell surface. 
Cells were then ﬁ  xed as described in Immunoﬂ  uorescence microscopy. To 
reveal the distribution of the primary antibody, AlexaFluor488-conjugated 
donkey anti–rat (Invitrogen) was used for the rat anti–mouse VEGFR-2. For 
the recombinant E-tagged anti–human VEGFR-2, rabbit anti–E-tag (Abcam) 
followed by AlexaFluor488-conjugated donkey anti–rabbit (Invitrogen) 
were used.
Cell surface biotinylation and immunoprecipitation. Internalization, 
recycling, and degradation were measured as described previously by 
Fabbri et al. (1999) with the following modiﬁ  cations. Cells were put on ice 
and washed three times with ice-cold PBS containing Ca
2+ and Mg
2+ 
(Ca
2+/Mg
2+ PBS). For surface biotinylation, cells in Ca
2+/Mg
2+ PBS were 
treated with 0.5 mg/ml of thiol-cleavable Sulfo-NHS-S-S-Biotin (Pierce 
Chemical Co.) for 1 h on ice. They were then washed on ice twice with 
Ca
2+/Mg
2+ PBS, once with MCDB 131, and once with 1% BSA MCDB 
131. 80 ng/ml VEGF in fresh 1% BSA MCDB 131 was added, and cells 
were incubated at 37°C for the time indicated to allow internalization. The 
cultures were then put back on ice and washed three times with ice-cold 
Ca
2+/Mg
2+ PBS. Samples were incubated twice for 20 min with 45 mM of 
the membrane-nonpermeable reducing agent GSH in 75 mM NaCl, with 
75 mM NaOH and 1% BSA added just before use (stripping buffer). Cells 
were further washed twice on ice with Ca
2+/Mg
2+ PBS and incubated for 
15 min with iodoacetamide (in Ca
2+/Mg
2+ PBS with 1% BSA; quenching 
buffer) to quench free sulfo-reactive groups. To evaluate total labeling, 
a sample for each cell type was not reduced with GSH. To control back-
ground, a sample was labeled and reduced without incubation at 37°C.
For immunoprecipitation, cells were washed with Ca
2+/Mg
2+ PBS 
and extracted on ice in 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton 
X-100, 1% NP-40, and a cocktail of protease inhibitors (Set III; Calbiochem). 
Extracts were precleared for 90 min with protein A–agarose beads and 
  incubated overnight with 5 μg anti–VEGFR-2 (rabbit sc-504), and the 
  immunocomplexes were collected on protein A–agarose beads for 90 min. 
After ﬁ  ve washes in extraction buffer (the last one containing 0.1% Triton 
X-100), proteins were eluted by boiling for 10 min in nonreducing laemmli 
sample buffer. Samples were analyzed by SDS-PAGE followed by Western 
blotting on nitrocellulose membrane and revealed by ECL chemilumines-
cence. Band intensity was quantiﬁ  ed by ImageJ analysis (National Insti-
tutes of Health; freely available at http://rsb.info.nih.gov/ij/).JCB • VOLUME 174 • NUMBER 4 • 2006  602
To quantify VEGFR-2 recycling and degradation, cells were labeled 
as described in the ﬁ  rst paragraph of this section, and endocytosis was al-
lowed for 10 min in the presence of 80 ng/ml VEGF (peak time for VEGF-
induced VEGFR-2 internalization both in VEC-null and -positive cells as 
determined in internalization experiments). Samples were then reduced as 
described in the ﬁ  rst paragraph of this section to remove the label from the 
residual cell surface receptor. The internalized fraction was chased by re-
incubation at 37°C for 10 and 20 min in duplicate samples. One sample 
was reduced to evaluate the amount of VEGFR-2 that recycled back to the 
plasma membrane, and the other sample was left unreduced to measure 
degradation. The samples were then processed as described in the ﬁ  rst 
paragraph of this section. VEGFR-2 degradation was calculated by sub-
tracting the value of residual biotinylated receptor after incubation at 37°C 
without reduction (i.e., internalized + recycled − degraded) from the total 
pool of internalized receptor. VEGFR-2 recycling was calculated by sub-
tracting both the degradation value and the value of residual biotinylated 
receptor after incubation at 37°C and reduction (i.e., internalized − recycled 
− degraded) from the total pool of internalized receptor.
Immunoﬂ  uorescence microscopy
Cells were cultured in 35-mm diameter petri dishes as described in Cell 
types and culture conditions. After the treatments indicated in the speciﬁ  c 
sections, culture medium was removed, and cells were ﬁ  xed in 1% PFA in 
2.5 mM triethanolamine, pH 7.5, containing 0.1% Triton X-100 and 0.1% 
NP-40 for 25 min at RT (Lallemand et al., 2003). Before staining, 0.5% 
  Triton X-100 in PBS was added for 10 min at RT. In some experiments, 
  immunoﬂ   uorescence microscopy for VEGFR-2 was performed using the 
Avas12α1 antibody after cell ﬁ   xation (in vitro staining). The ﬁ  xation/ 
permeabilization method applied (Lallemand et al., 2003) allows an optimal 
observation of VEGFR-2 in internal compartments with in vitro staining 
  (primary antibody after cell ﬁ  xation). Data obtained with in vivo (see Internal-
ization assays) and in vitro staining were superimposable for both VEC’s 
effect on VEGFR-2 vesicular labeling and the codistribution of VEGFR-2 
with markers of speciﬁ  c compartments such as EEA-1 and caveolin-1. A com-
parison of VEGFR-2 vesicular distribution after in vivo staining (with and 
without acid wash before ﬁ  xation) is shown in Fig. S5.
In some experiments (in particular for clathrin detection), ﬁ  xation was 
performed in 1% PFA, and permeabilization was performed with 0.02% 
saponin that was maintained for all of the staining procedure.   Fluorophore-
labeled secondary antibodies produced in donkey had minimal cross-
  reactivity to other species except for the targeted species (Invitrogen). 
Anti–VEGFR-2 was revealed with AlexaFluor488-conjugated secondary 
  antibodies (anti–rat for anti–mouse VEGFR-2 and anti–rabbit for anti–  human 
VEGFR-2). In double labeling experiments, AlexaFluo488- and -647 ﬂ  uoro-
chromes were used to stain each of the two antigens, respectively.
Samples were observed under a ﬂ   uorescence microscope (DMR; 
Leica) using 63× and 100× lenses. Images were captured using a charge-
coupled camera (model 3; Hamamatsu) before processing through Adobe 
Photoshop for MacIntosh. Quantiﬁ   cation of vesicular labeling was per-
formed using the ImageJ program (version 10.2). For comparison pur-
poses, different sample images of the same antigen were acquired under 
constant acquisition settings. The best-ﬁ  t lower threshold to eliminate most 
of the signal background was determined using the threshold tool and con-
ﬁ   rmed by visual inspection and count of one-pixel dimension particles. 
In some cases, the same sample was analyzed at different lower thresholds 
to determine the best ﬁ  t. Upper threshold was always set at 255. Particles 
with a minimum size of ﬁ  ve pixels were counted. For colocalization analy-
sis, images were acquired using a confocal microscope (TCS SP2 AOBS; 
Leica) with a 63× objective and a 3× zoom. Colocalization was quanti-
ﬁ  ed using the colocalization plugin of ImageJ. The channel ratio was al-
ways set at 90%. For both channels, the best-ﬁ  t lower threshold value to 
remove most background signal was determined using the threshold tool 
as described above.
EM
For immunogold labeling, 4% PFA/0.4% glutaraldehyde in PBS was added 
in a 1:1 ratio to culture medium. After 2 h at RT, the ﬁ  xative was discarded, 
and cells were scraped in 1% PFA in PBS, collected in Eppendorf tubes, 
and processed for ultrathin cryosectioning as described previously 
  (Confalonieri et al., 2000). Double immunogold labeling was performed 
as described previously (Slot et al., 1991).
Cell fractionation, extraction, and Western blotting
Subcellular fractionation on an iodixanol gradient was performed as de-
scribed previously (Yeaman et al., 2001). Cells were cultured in 150 cm
2 
ﬂ  asks as described in Cell types and culture conditions. Three ﬂ  asks per 
gradient were used. After the indicated treatments, cultures were put on ice 
and washed twice with ice-cold PBS. Cells were scraped in 1.2 ml of ice-
cold isotonic buffer/ﬂ  ask (20 mM Hepes-KOH, pH 7.5, 0.25 M sucrose, 
90 mM KO-acetate, 2 mM Mg-acetate, 0.5 mM Na-vanadate, 1 mM NaF, 
10 mM pyrophosphate, 3 mM β-glycerophasphate, 1 mM pefabloc, 
40 U/ml aprotinin, 10 μg/ml leupeptin, and 10 μg/ml pepstatin) and ho-
mogenized with a Dounce homogenizer. Nuclei and residual intact cells 
were pelleted by centrifugation at 1,400 g for 5 min at 4°C. The superna-
tants were separated in three equal aliquots and mixed with iodixanol 
(OptiPrep; Axis-Shield) and homogenization buffer to generate 30, 20, 
and 10% iodixanol solutions. They were then loaded into 11.2-ml 
OptiSeal tubes (Beckman Coulter) and ultracentrifuged at 353,000 g for 
3 h in a rotor (VT 65.1; Beckman Coulter). 600-μl fractions were collected 
from the top of the gradient, and protein concentration (bicinchoninic acid 
reagent; Pierce Chemical Co.) and density (OD at 244 nm as indicated by 
the OptiPrep manufacturer) were determined. The fractions were then 
boiled in the presence of reducing laemmli sample buffer. Samples of each 
fraction containing the same amount of protein for the different cell types 
to be compared and representative of the total protein content of each 
fraction were analyzed by SDS-PAGE followed by Western blotting.
For total cell extracts, cells were washed twice in PBS, extracted in 
2× boiling laemmli sample buffer (200 μl for a 35-mm petri dish) containing 
100 mM DTT, scraped, and boiled for a further 10 min. Parallel samples 
were extracted without DTT, and protein concentration was determined 
by bicinchoninic acid analysis. A total of 15 μg of protein was loaded in 
each lane and separated by SDS-PAGE, transferred onto nitrocellulose, 
and immunoblotted with the indicated antibodies.
For detection, HRP-conjugated horse anti–mouse, goat anti–rabbit 
(Cell Signaling), and rabbit anti–goat (DakoCytomation) secondary anti-
bodies and ECL chemiluminescence reagent (GE Healthcare) were used. 
Films were scanned and bands were quantiﬁ  ed using ImageJ set on the un-
calibrated OD function. Adobe Photoshop 7.0, Excel X for MacIntosh, and 
Adobe Illustrator 11 for the PC were used to produce the ﬁ  gures presented.
Online supplemental material
Fig. S1 shows that PV-1 colocalizes with caveolin in VEC-null and -positive 
cells. Fig. S2 shows that cell conﬂ  uence modulates VEGF-induced PY1175–
VEGFR-2–positive compartments in HUVECs. Fig. S3 shows that clathrin 
siRNA inhibits the formation of clathrin-positive vesicular compartments. 
Fig. S4 shows that the cytoplasmic domain of VEC is required to modulate 
VEGFR-2 internalization from the plasma membrane. Fig. S5 shows that 
the antibody Avas12α1 does not modify either the basal or VEGF-  stimulated 
tyrosine phosphorylation of VEGFR-2 and does not induce VEGFR-2 inter-
nalization. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200602080/DC1.
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